Linarol-M Tablet 2.5 mg+500 mg is a combination oral antidiabetic medication containing Linagliptin (2.5 mg) and Metformin Hydrochloride (500 mg). It is specifically formulated for the management of type 2 diabetes mellitus in adults whose blood sugar levels are inadequately controlled with diet, exercise, or monotherapy.

This combination offers dual-action glycemic control: Linagliptin, a DPP-4 inhibitor, enhances insulin secretion and reduces glucagon release in a glucose-dependent manner, while Metformin improves insulin sensitivity in peripheral tissues and decreases hepatic glucose production. Together, these effects provide comprehensive control of fasting and postprandial blood glucose levels, helping to reduce the risk of long-term diabetes-related complications.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Linarol-M Tablet combines the mechanisms of its two active ingredients:

• Linagliptin (2.5 mg): Inhibits the DPP-4 enzyme, prolonging the activity of incretin hormones (GLP-1 and GIP). This increases insulin secretion when blood glucose is elevated and reduces glucagon release, decreasing hepatic glucose output.

• Metformin (500 mg): Enhances insulin sensitivity in muscles and adipose tissue, reduces glucose production by the liver, and improves peripheral glucose utilization.

• Synergistic effect: Together, these components provide sustained glycemic control, reduce post-meal glucose spikes, and help maintain stable blood sugar levels.

This combination is especially advantageous for patients who require more comprehensive management of type 2 diabetes than monotherapy can provide.

Indications

Linarol-M Tablet 2.5 mg+500 mg is indicated for:

• Type 2 diabetes mellitus: For patients not adequately controlled with diet, exercise, or monotherapy with Linagliptin or Metformin.

• Combination therapy for optimal glycemic control: Can be used as part of a regimen with other oral antidiabetic agents or insulin.

• Postprandial glucose management: Helps prevent high blood sugar spikes following meals.

It is not suitable for type 1 diabetes, diabetic ketoacidosis, or patients with severe renal or hepatic impairment.

Dosage and Administration

• The typical dose is 1 tablet twice daily, taken with meals to reduce gastrointestinal side effects of Metformin.

• Swallow the tablet whole with water; do not crush or chew.

• Dosage may be adjusted according to blood glucose levels, HbA1c, and clinical response under medical supervision.

• Regular monitoring of fasting and postprandial glucose, as well as HbA1c, is recommended.

• Continue adhering to dietary measures, exercise, and lifestyle modifications for optimal glycemic control.

Precautions

• Use with caution in patients with renal or hepatic impairment; Metformin carries a rare risk of lactic acidosis.

• Hypoglycemia may occur due to Linagliptin when used with sulfonylureas or insulin.

• Inform your doctor about any heart disease, pancreatitis, adrenal/pituitary disorders, or history of lactic acidosis.

• Limit alcohol intake, as it may increase the risk of hypoglycemia or lactic acidosis.

• Consult your physician before use during pregnancy or breastfeeding.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects include:

• Hypoglycemia (dizziness, sweating, fatigue, confusion)

• Gastrointestinal disturbances: nausea, vomiting, diarrhea, or mild abdominal discomfort

• Headache

• Joint pain

Rare but serious side effects include:

• Pancreatitis (severe abdominal pain, nausea, vomiting)

• Severe allergic reactions (rash, swelling, difficulty breathing)

• Lactic acidosis (very rare but serious)

Seek immediate medical attention if severe or persistent symptoms occur.

Storage

Store below 30°C in a dry place, protected from sunlight and moisture. Keep out of reach of children.

Linarol-M Tablet 2.5 mg+500 mg provides effective dual-action therapy for type 2 diabetes, combining Linagliptin and Metformin to maintain stable blood sugar, enhance insulin function, and reduce long-term complications under proper medical supervision.